JP2018513141A5 - - Google Patents

Download PDF

Info

Publication number
JP2018513141A5
JP2018513141A5 JP2017551169A JP2017551169A JP2018513141A5 JP 2018513141 A5 JP2018513141 A5 JP 2018513141A5 JP 2017551169 A JP2017551169 A JP 2017551169A JP 2017551169 A JP2017551169 A JP 2017551169A JP 2018513141 A5 JP2018513141 A5 JP 2018513141A5
Authority
JP
Japan
Prior art keywords
cancer
cdr
seq
residues
epitope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017551169A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018513141A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/058527 external-priority patent/WO2016169581A1/en
Publication of JP2018513141A publication Critical patent/JP2018513141A/ja
Publication of JP2018513141A5 publication Critical patent/JP2018513141A5/ja
Pending legal-status Critical Current

Links

JP2017551169A 2015-04-20 2015-04-20 ヒトカドヘリン−17、ヒトカドヘリン−5、ヒトカドヘリン−6およびヒトカドヘリン−20のrgdモチーフに特異的に結合する薬剤 Pending JP2018513141A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2015/058527 WO2016169581A1 (en) 2015-04-20 2015-04-20 Agents binding specifically to human cadherin-17, human cadherin-5, human cadherin-6 and human cadherin-20 rgd motif

Publications (2)

Publication Number Publication Date
JP2018513141A JP2018513141A (ja) 2018-05-24
JP2018513141A5 true JP2018513141A5 (https=) 2018-07-05

Family

ID=52875715

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017551169A Pending JP2018513141A (ja) 2015-04-20 2015-04-20 ヒトカドヘリン−17、ヒトカドヘリン−5、ヒトカドヘリン−6およびヒトカドヘリン−20のrgdモチーフに特異的に結合する薬剤

Country Status (6)

Country Link
US (1) US10829560B2 (https=)
EP (1) EP3286218B1 (https=)
JP (1) JP2018513141A (https=)
AU (1) AU2015392603B2 (https=)
ES (1) ES2939013T3 (https=)
WO (1) WO2016169581A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2703949C1 (ru) * 2018-04-27 2019-10-22 Открытое акционерное общество "Всероссийский научный Центр молекулярной диагностики и лечения" (ОАО ВНЦМДЛ) Вариабельные домены лёгкой и тяжёлой цепи мышиного моноклонального антитела против кадгерина-17 человека, антигенсвязывающий фрагмент (Fab) против кадгерина-17 человека, содержащий указанные домены
US20210116456A1 (en) * 2018-05-16 2021-04-22 Arbele Limited Compositions and methods for diagnosis and treatment of cancer
CN111349157B (zh) * 2018-12-21 2023-06-23 艾比玛特医药科技(上海)有限公司 钙粘附蛋白6的单克隆抗体及其应用
JP7249579B2 (ja) * 2019-02-20 2023-03-31 日本電信電話株式会社 細胞接着基板及びその製造方法
AU2022406708A1 (en) * 2021-12-10 2024-06-27 Multitude Therapeutics Inc. Anti-cdh6 antibodies and antibody-drug conjugates thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2003038096A1 (ja) 2001-10-30 2005-02-24 俊一郎 久保田 血管新生阻害因子に対する受容体および血管新生阻害因子のスクリーニング方法
CA2566257A1 (en) 2004-05-07 2005-11-24 Applera Corporation Genetic polymorphisms associated with vascular diseases, methods of detection and uses thereof
DE102004023187A1 (de) * 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
DK2421898T3 (en) 2009-04-20 2016-05-30 Oxford Biotherapeutics Ltd Cadherin-17 SPECIFIC ANTIBODIES
KR101809761B1 (ko) 2009-09-24 2017-12-15 가부시키가이샤 진 테크노 사이언스 세포 외 기질 단백질의 아미노산 서열 rgd에 특이적인 인간화된 항체 및 그의 용도
KR101398079B1 (ko) 2011-10-10 2014-05-27 재단법인 의약바이오컨버젼스연구단 글리실-티알엔에이 합성효소 및 캐드헤린을 이용한 암 예방 또는 치료제의 스크리닝 방법
HK1214652A1 (zh) * 2013-03-13 2016-07-29 克里蒂科斯有限责任公司 用於检测胰腺癌的方法和组合物

Similar Documents

Publication Publication Date Title
CN111454357B (zh) 一种含有抗体的肿瘤治疗剂的开发和应用
RU2019128134A (ru) Антитело против gprc5d и молекула, содержащая антитело
RU2017145150A (ru) Антитело против pdl-1, его фармацевтическая композиция и применение
JP2015163068A5 (https=)
JP2020510422A5 (https=)
JP2019507135A5 (https=)
JP2014158469A5 (https=)
JP2020500003A5 (https=)
JP2020522488A5 (https=)
JP2020534830A5 (https=)
JPWO2020114480A5 (https=)
JP2011207882A5 (https=)
JP2013502913A5 (https=)
JP2021517152A5 (https=)
JP2010516708A5 (https=)
NZ597067A (en) Monoclonal antibodies expressed by ATCC PTA-4621 for the treatment of cancer
JP2018513141A5 (https=)
JP2026041845A5 (https=)
JP2018505681A5 (https=)
JP2019205480A5 (https=)
JP2019513410A5 (https=)
JP2024001073A5 (https=)
JP2018528759A5 (https=)
JP2021518415A5 (https=)
CN115461373A (zh) 密蛋白18.2的抗体及其用途